Archives

FDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

B CAPLYTA® reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months Demonstrating long-term stability and a well-established… Login to continue reading Login…

Read MoreFDA approves CAPLYTA® (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia

Republic of Colombia Announces Final Results of Tender Offer and Aggregate Principal Amount of Tenders Accepted for Purchase

B BOGOTA, Colombia, April 27, 2026 /PRNewswire/ — The Republic of Colombia (“Colombia“) previously announced a tender offer (the “Tender Offer“) to purchase its outstanding… Login to continue reading Login…

Read MoreRepublic of Colombia Announces Final Results of Tender Offer and Aggregate Principal Amount of Tenders Accepted for Purchase